2 . Today’s Brussels sprouts (孢子甘蓝) taste better than you might remember from childhood, and that is because a new variety has replaced the original vegetable. You can thank plant breeders (植物育种家) for the change. Modern breeders, armed with new gene-editing technology, are looking to reproduce Brussels sprouts’ reinvention.

In the late 1990s, scientists discovered specific chemicals which made Brussels sprouts taste bitter. Plant breeders started growing old seeds, previously abandoned due to poor yields (产量), to look for tastier versions with lower levels of these specific chemicals. Then they crossed these delicious but low-yield plants with high-yield individuals until they found a version that made plenty of tasty sprouts, transforming the vegetable from a bitter pill into a popular dish.

But other vegetables haven’t fared as well. That’s because most breeding decisions favor plant traits that matter to vegetable growers, not vegetable eaters. For instance, disease resistance is probably the major focus these days of most breeding programs because that prevents the farmer from growing the crop. The taste of vegetables is ignored.

People, however, are now becoming interested in prioritizing the taste of vegetables thanks in part to new genetic technology such as the gene-snipping technique CRISPR and DNA sequencing which is cheap enough to use widely. “There’s never been a better time to be a fruit breeder or a vegetable breeder because we have more tools and techniques,” says Susan Brown, an apple breeder at Cornell University.

Some companies are beginning to use those tools to deal with the challenge of developing tastier vegetables. One company, Pairwise, is fighting the same compounds that troubled Brussels sprouts: glucosinolates. But this time researchers are improving the flavor of salad greens.

All vegetable growers hope that more flavorful products on store shelves will convince people to consume the recommended allowances (推荐量) of fruits and vegetables — and do so better than decades of nutritional guidance have. “Don’t waste your time talking about trying to educate people to eat better,” said Harry Klee, a professor who specializes in tomato breeding. “Just give them products that taste better and that they want to eat.”

4 . Antibiotics, which can destroy or prevent the growth of bacteria and cure infections, are vital to modern medicine. Their ability to kill bacteria without harming the patient has saved billions of lives and made surgical procedures much safer. But after decades of overuse, their powers are fading. Some bacteria have evolved resistance, creating a growing army of superbugs, against which there is little effective treatment. Antimicrobial (抗菌的) resistance, expected to kill 10 million people a year by 2050 up from around 1 million in 2019, has been seen as a crisis by many.

It would be unwise to rely on new antibiotics to solve the problem. The rate at which resistance emerges is increasing. Some new drugs last only two years before bacteria develop resistance. When new antibiotics do arrive, doctors often store them, using them only reluctantly and for short periods when faced with the most persistent infections. That limits sales, making new antibiotics an unappealing idea for most drug firms.

Governments have been trying to fix the problem by channeling cash into research in drug firms. That has produced only limited improvements. But there is a phenomenon worth a look. Microbiologists have known for decades that disease-causing bacteria can suffer from illnesses of their own. They are supersensitive to attacks by phages, specialized viruses that infect bacteria and often kill them. Phages are considered a promising alternative to antibiotics.

Using one disease-causing virus to fight bacteria has several advantages. Like antibiotics, phages only tend to choose particular targets, leaving human cells alone as they infect and destroy bacterial ones. Unlike antibiotics, phages can evolve just as readily as bacteria can, meaning that even if bacteria do develop resistance, phages may be able to evolve around them in turn.

That, at least, is the theory. The trouble with phages is that comparatively little is known about them. After the discovery of penicillin, the first antibiotic, in 1928, they were largely ignored in the West. Given the severity of the antibiotic-resistance problem, it would be a good idea to find out more about them.

The first step is to run more clinical trials. Interest from Western firms is growing. But it is being held back by the fact that phages are an even less appealing investment than antibiotics. Since they are natural living things, there may be trouble patenting them, making it hard to recover any investment.

Governments can help fun d basic research into phage treatment and clarify the law around exactly what is and is not patentable. In time they can set up phage banks so as to make production cheaper. And they can spread awareness of the risks of overusing antibiotics, and the potential benefits of phages.

5 . Most glitter(小发光物品), which is made up of tiny pieces of plastic, is a huge danger to the environment. “Everyone talks about the mountain of plastic floating in the ocean. You can grab empty bottles from the water, but with tiny pieces, it’s impossible,” says Victor Alvarez, a chemical engineer who sells an eco-friendly alternative to glitter.

In the early 2,000s, Alvarez worked for Mercedes-Benz in Germany, where he became fond of any technology that protected the environment. A few years after leaving Mercedes-Benz, he founded Blue Sun International in Miami, which makes specialty ingredients for the skin and hair care industries.

Glitter is a popular ingredient in cosmetics, such as eye shadows and lipsticks. So Alvarez began researching an alternative that didn’t contain plastic to make his products safer for the environment. That’s when he came across Ronald Britton Ltd., a company which had developed a plastic-free, biodegradable product called Bioglitter. It is made from regenerative cellulose(纤维素) sourced from hardwoods, primarily eucalyptus(桉树). Alvarez worked with the company to become the first retailer to sell Bioglitter in America. In 2018, he formed Today Glitter in order to sell the biodegradable glitter directly to consumers through its website.

Today Glitter sells two kinds of biodegradable glitter Bioglitter Sparkle and Bioglitter Pure. Both are almost plastic-free and can biodegrade in a short time. Meanwhile, they are as shiny as regular glitter. All these products are third-party tested by TÜV, an international organization that provides testing and certification for compostable (可降解的) and biodegradable products.

Despite its benefits, the hardwoods needed to make biodegradable glitter cause it to cost about twice as much as conventional glitter. A small glass container that contains just 6 grams of Bioglitter costs $10, while the same amount of regular glitter could cost at least half that amount. Alvarez expects the price will come down over time. He also expects the company’s sales to cross $1 million next year. But more importantly, Alvarez says, his main goal is to effect a meaningful change.

6 . People solve some new problems readily without any special training or practice by comparing them to familiar problems and extending the solutions to the new problems. That process, known as analogical reasoning (类比推理), has long been thought to be an ability only humans have. But now people might have to make room for a new kid on the block.

Psychologists from the University of California, Los Angeles (UCLA) claim that, astonishingly, the artificial intelligence (AI) language model GPT-3 performs about as well as college undergraduates when asked to solve the sort of reasoning problems that typically appear on intelligence tests and standardized tests.

But the psychologists raise the question: Is GPT-3 copying human reasoning as a by-product of its massive language training data set or using a fundamentally new kind of cognitive (认知的) process? They also say that although GPT-3 performs far better than they expected at some reasoning tasks, the popular AI tool still fails completely at others. “It can do analogical reasoning, but it can’t do things that are very easy for people, such as using tools to solve a physical task,” says Taylor Webb, a UCLA postdoctoral researcher in psychology.

Webb and his colleagues tested GPT-3’s ability to solve a set of problems inspired by a test known as Raven’s Progressive Matrices, which ask the subject to predict the next image in a complicated arrangement of shapes. To enable GPT-3 to “see” the shapes, and make sure that the AI tool had never met the questions before, Webb transformed the images into a text format that GPT-3 could process.

The psychologists asked 40 UCLA undergraduate students to solve the same problems. Surprisingly, not only did GPT-3 do about as well as humans but it made similar mistakes as well. GPT-3 solved 80% of the problems correctly — well above the human subjects’ average score of just below 60%, but within the range of the highest human scores.

7 . A comment from Zadie Smith caught my attention this week. Asked whether she had ever considered recording an album, the novelist responded, “I have a dream of having a Café Carlyle residency in New York in my 80s.” Here she is at the height of her success dreaming of a career Plan B just like the rest of us!

Weird Plan Bs fascinate me because for years I had one of my own. Despite being perfectly happy in my chosen profession, I had long harboured the fantasy of becoming a photographer and I took a lockdown leap and applied to art school to acquire some actual skills.

Has it brought me fame and riches? Not as yet. Like many people who dream of having a go at something different, I was focusing on creative fulfilment rather than my future finances. By the time I graduated in 2022, my dream of running a portrait photography business was looking a lot less practicable—in part thanks to AI head-shot generators.

If only I had had a little more Fobo, also known as the fear of becoming out-of-date. This workplace trend is an updated version of Fomo—the fear of missing out, which now feels like a poignant (辛酸的) throwback to more optimistic times. 22% of workers are worried that technology will put them out of a job. And who can blame them?

There is another reason that nurturing an alterative career might be risky. Research indicates that having a back-up plan can work against you. Having a Plan B as a safety net can cause people to make less effort at their day job and — unhelpfully — run a greater risk of losing it.

So, do I regret pursuing my Plan B? Not at all — hopefully I’ve got a few years before robot photographers take over the world, and I currently spend a day a week on photography. My only sorrow is something unexpected. For so many years. I had the fantasy of trying something new. My “someday” ambition sustained me through dull and boring days. But now I’m actually spending some of my week doing it, which has caused empty space in my life. It made me realize that having an alternative career to dream about is in itself sustaining and comforting. You might never do it, and that might not even matter. So, if you’ll excuse me, I need to go and start working on my Plan C...

8 . Researchers have claimed a major step forward in the field of organ transplantation after a monkey survived for more than two years with a genetically engineered pig kidney.

Scientists have spent decades working out whether animal organs could ever work properly and safely in humans without them being rejected by the patient’s immune system, but the challenges have proved immense.

For the latest trial, researchers used a gene-editing tool called Crispr to alter genes in Yucatan miniature pigs before transplanting their kidneys into macaques (猕猴). The modifications altered genes to prevent organ rejection and remove pig viruses that could potentially be activated in recipients.

Writing in the journal Nature, the scientists describe how 21 monkeys got on after their kidneys were removed and a single genetically modified pig kidney was implanted. Monkeys typically survived no more than 24 days when the kidneys were edited to disable three genes that triggered immune rejection. But when the scientists added seven human genes that reduce blood clotting (结块), inflammation and other immune reactions, the monkeys survived seven times longer, typically for 176 days. When combined with treatment to restrain the immune system, the researchers report that one monkey survived for more than two years — 758 days — with the transplanted organ.

Curtis, the chief executive of eGenesis, said the long-term survival of at least some of the monkeys had put eGenesis on course to satisfy the US Food and Drug Administration requirement to see at least 12 months’ survival in animals before the team can launch a clinical trial in humans. “We are well on our way there,” Curtis said. “There simply aren’t enough kidneys to go around. In our opinion it’s the only near-term practicable solution.”

The team uses Yucatan miniature pigs as donors because at maturity their kidneys are roughly the same size of those in the adult human. In the monkey trial, the kidneys were transplanted at two to three months when the organs were much smaller.

Prof Tatsuo Kawai, an author on the study at Harvard Medical School, said the scientists expected the modified pig organs to perform better in humans than monkeys because “they are a better match”.

9 . Plato believed that men are divided into three classes: gold, silver and bronze. Vilfredo Pareto, an Italian economist, argued that “ the vital few” contributed to most progress. Such viewpoints are taboo (禁忌) today in public life. Politicians avoid talking of a “leadership class” or “the vital few”. School recruitment turns away from picking winners. Universities welcome the masses: more people now teach at British universities than attended them in the1950s.

In the private sector things could hardly be more different. The world’s best companies struggle tirelessly to find and keep the vital few. They offer them fat pay packets, extra training, powerful instruction and more challenging assignments. Private-equity (私人股权) firms rely heavily on a few stars. Firms in emerging markets are desperate to find high-flyers who can cope with rapid growth and fast-changing environments.

Few people know more about how companies manage talent than Bill Conaty and RamCharan. Mr. Conaty led the human-resources department at General Electric (GE) for 14years. Mr. Charan has spent the past few decades presenting proposals to some celebrated entrepreneurs (企业家). Their recent book, The Talent Masters, provides. a nice mix of portraits of well-known talent factories, such as GE and Procter & Gamble (P&G).

Successful companies make sure that senior managers are involved with “ talent development”. Jack Welch and A. G. Lafley, former bosses of GE and P&G, claimed that they spent 40% of their time on personnel. Andy Grove, who ra n Intel, a chipmaker, obliged all the senior people, including himself, to spend at least a week a year instructing high-flyers . Nitin Paranjpe, the boss of Hindustan Unilever, recruits people from campuses and regularly visits high-flyers in their offices.

Elitism (精英主义) has its drawbacks. In their rush to classify people, companies can miss potential stars. Those who are singled out for special treatment can become too full of themselves.